Strategikon Closes Series A1 Funding Round to Modernize Clinical Trials Business Operations Worldwide

Feb 06, 2024•over 1 year ago

Amount Raised

$7 Million

San FranciscoPharmaceuticalBiotechnology

Investors

Golden SeedsHearst LabDebiopharm Innovation FundOsage Venture Partners

Description

Strategikon has closed an over-subscribed $7.0M Series A1 financing round led by Osage Venture Partners, Debiopharm Innovation Fund, HearstLab, and Golden Seeds. The funding milestone underscores the belief in Strategikon's vision to redefine strategic intelligence in the pharmaceutical landscape.

Company Information

Company

Strategikon

Location

San Francisco, California, United States

About

At Strategikon Pharma, our mission is to lower the cost and expedite the time to market of new medical treatments through built-for-purpose cloud-based solutions that improve and accelerate the planning and outsourcing of clinical trials. The experts at Strategikon developed Clinical Maestro out of a combination of love and frustration. The system was developed and nurtured by financial and clinical business operations executives with both Sponsor and Provider experience. Our founders believed there had to be a better way — and so they created one.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns